Novartis tests new drug combo for Tough-to-Treat blood cancer
NCT ID NCT04123418
Summary
This early-stage study aimed to find a safe dose of a new drug called WVT078, given alone and with another drug called WHG626, for people with advanced multiple myeloma. It involved 56 patients whose cancer had returned or stopped responding to at least two standard treatments. The main goal was to check for side effects and determine the best dose for future testing, not to cure the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113-8677, Japan
-
Novartis Investigative Site
Oslo, NO-0407, Norway
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
University Of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.